Background: The immune system is a complex adaptive system of cells and molecules that are interwoven in a highly organized communication network. Primary immune deficiencies are disorders in which essential parts of the immune system are absent or do not function according to plan. X-linked agammaglobulinemia is a B-lymphocyte maturation disorder in which the production of immunoglobulin is prohibited by a genetic defect. Patients have to be put on life-long immunoglobulin substitution therapy in order to prevent recurrent and persistent opportunistic infections.
Introduction
Adaptive immunity implies immune responses against pathogenic challenges that are antigen-specific and that are memorized by the immune system. On encounter of antigen, B-lymphocytes are stimulated to differentiate into plasma cells which produce large amounts of immunoglobulin. These proteins are specific for those antigens that stimulate their production and play a key role in adaptive immunity: Immunoglobulin fights off bacterial infections by the specific recognition of the invading pathogens, the neutralization of their harmful effects, and their opsonization for phagocytosis [1, 2] .
In order to specifically bind to the vast amount of different antigens, the molecular structure of immunoglobulin contains a hypervariable region. This region is generated by random combinations of gene segments that encode a large variety of antigen binding sites and that give rise to a highly diverse repertoire of immunoglobulin. The immunoglobulin binding affinity for an encountered antigen is dynamically optimized in the process of affinity maturation that takes place in germinal centers. Germinal centers are follicular structures in lymphoid organs where B-lymphocytes undergo the process of somatic hypermutation with regard to the immunoglobulin hypervariable region [3] [4] [5] . This is followed by the complex process of Blymphocyte selection for high-affinity immunoglobulin, which we only start to unravel today [6] . Successfully selected B-lymphocytes either differentiate into plasma cells or into long-lived memory cells. The latter give rise to faster and stronger immune responses on second encounter of the same antigen. In this way the highly diverse immunoglobulin repertoire is dynamically adapted to the host's current antigenic environment.
In humans, five different immunoglobulin isotypes are distinguished that differ in their biological and functional properties [2] . The most prevalent isotype is immunoglobulin G (IgG), which constitutes about 75% of all serum immunoglobulin and is equally distributed in blood and in tissue. IgG is the only isotype that crosses the human placenta thereby protecting the fetus in utero and providing neonates with passive immunity for the first six months of their life, before the infant's immune system starts to produce its own immunoglobulin. Thus, rather than being present at birth, adaptive immunity is an acquired property of the developing immune system in healthy infants.
Patients with immune deficiencies suffer from recurrent and persistent infections that develop as the result of a compromised immune system [7] . For example, X-linked agammaglobulinemia (XLA) is a primary immune deficiency that is characterized by absent levels of immunoglobulin for all isotypes [8] [9] [10] . This disease is caused by a mutation of Bruton's tyrosine kinase (Btk gene) on the X chromosome [11, 12] and affects male and homozygous female subjects. The genetic defect prohibits the full maturation of B-lymphocytes such that their vital function in immunoglobulin adaptation and production remains unaccomplished. Recurrent infections in infants starting after the first six months of life, particularly involving extracellular bacteria, are typical phenomena belonging to the XLA diagnosis. Untreated XLA patients are prone to develop severe and life-threatening infections, however, this risk is significantly lowered by IgG substitution therapy. The life-long, exogenously induced passive immunity compensates the absence of adaptive immunity as mediated by the B-lymphocytes and enables XLA patients to live a fairly normal life.
Under IgG substitution therapy, a fixed dose of IgG is periodically administered by infusion, such that the serum IgG level always remains above a trough level [13] [14] [15] [16] . The pool of immunoglobulin is extracted from the blood products of more than 10 3 human donors in order to reach up to 10 9 different immunoglobulin specificities [13] . Nowadays, IgG substitution treatments are performed by intravenous (IV) or subcutaneous (SC) infusion that both have assets and drawbacks [15, [17] [18] [19] . For example, IV infusion allows the administration of large IgG amounts per treatment such that low treatment frequencies down to one treatment per four weeks can be achieved. However, this IV treatment protocol gives rise to high serum IgG peak levels that significantly exceed the physiological range, but are required in order to ensure acceptable serum IgG trough levels after four weeks. The drawback of SC infusion is associated with the limited amount of IgG that can be administered per treatment and that requires high treatment frequencies up to two times per week. However, this also infers serum IgG peak levels that remain close to the physiological range. Associated with this issue is the observation that adverse effects are much less reported for SC compared to IV infusion of IgG [19] . A practical advantage of SC over IV infusion is that this treatment can be autonomously performed by the patients and does not require medical supervision.
Besides immune deficiencies a number of autoimmune and systemic inflammation diseases are as well treated by IgG substitution therapy, even though it is not yet understood for all these diseases how IgG exerts its therapeutic impact [13, 14] . In general, the demand for therapeutic use of IgG is increasing at an annual rate of 5% in Europe and 11% in the US, prophesying that the current worldwide IgG shortage will pose a serious problem in the future [20, 21] . To optimize IgG consumption the appropriate dosage window of treatment, which is commonly derived from empirical trial-and-error methods, should be more precisely determined by all means. Using a mathematical model approach, we perform a comparative study of IgG substitution therapies for XLA patients in order to identify the range of optimal treatment frequencies. Characteristic features such as the serum IgG peak level, the dose per treatment, and the impact of fluctuations in the administered IgG dose are studied. Moreover, we consider the effect of bacterial infections and calculate the condition for the development of chronic infections under different IgG substitution therapies. The range of optimal treatment frequencies is then identified from the requirement that IgG levels should be kept close to physiological levels and are still effective at clearing infections. To our knowledge, we present the first immune response model for infections under IgG substitution therapy with a combined analysis of computer simulations and analytical calculations that permits to make quantitative predictions of therapeutic relevance.
Methods

Stochastic Immune Response Model
The stochastic immune response model for infections under IgG substitution therapy accounts for two aspects: (i) the serum IgG reduction by natural degradation or antigenic consumption, and (ii) the periodic IgG replenishment that may be subjected to fluctuations in the administered IgG dose. The model is schematically depicted in Figure 1A and is translated into a set of coupled differential equations. Since we are interested in describing serum IgG levels, this approach, in which spatial inhomogeneities are neglected, is justified by the fact that molecules in the blood stream are thoroughly mixed and quickly circulate on the time scale of 25 seconds [22] . Throughout this paper we measure concentrations of quantities relative to the blood volume in units of gram per liter.
The time-dependent serum IgG concentration, I m t ð Þ, obeys the differential equation
The source term S m t ð Þ represents the IgG substitution therapy, where the subscript m refers to the treatment frequency f m of the therapy protocol. Since the longest time interval between subsequent IV infusion treatments equals four weeks [14, 15] , we set T 1~2 8d and f 1~1 =T 1 . In order to compare therapy protocols with different treatment frequencies, we consider therapy protocols with multiples of this frequency:
where m is a positive integer number. The IgG reduction in Eq. (1) is represented by the rate r t ð Þ, which consists of two contributions:
Here, r d is the natural IgG degradation rate while the antigenic consumption depends on the current size of the bacteria population B m t ð Þ and the clearance rate r c . Note that the clearance rate is a reaction rate with unit (concentration6time) 21 . A large variety of sigmoidal growth models exists, describing the time-dependent growth of specific microbes under various nutrient conditions [23] [24] [25] . In the present context, we do not aim at modeling specific types of bacteria and apply a logistic growth model, which is known to capture the generic features of nutrientlimited bacterial growth beyond the lag-phase [25] . In the presence of the immune response the time-dependence of the bacteria population is determined by the differential equation:
Bacteria proliferate with rate r p to the nutrient-limited population size with carrying capacity C B in the absence of an immune response. Note that the subscript m indicates that the timeevolution of B m t ð Þ is affected through I m t ð Þ by the frequency f m of the therapy protocol.
The IgG substitution therapy is incorporated by the source term
where n labels treatments of duration T i at time points nT m , and
with
is the Dirac distribution. The appearance of the treatment duration T i in Eq. (5) is only artificial, since the Dirac distribution implies that infusion treatments are modeled as instantaneous processes. This simplification is justified by the fact that T i is of the order of hours, whereas the time between subsequent treatments is of the order of several days, T m &T i , and we are ultimately interested in the time-dependence of I m t ð Þ and B m t ð Þ at the time scale of weeks, t&T m &T i .
We account for fluctuations in the administered IgG dose per treatment,
where I m is the average administered IgG dose per treatment and c n ð Þ is a Gaussian distributed random variable referring to the n th treatment. The ensemble average S . . .T c yields the mean value Sc n ð ÞT c~0 ð8Þ , giving rise to IgG-bacterium complexes that are removed from the system. The bacteria population obeys a logistic growth dynamics that is characterized by the proliferation rate r p (self-activating process: R) and the carrying capacity C B (self-inhibiting process: x). B: The shape space is an abstract high-dimensional space, where essential features of IgG binding regions with respect to the considered bacteria species are represented as points. For reasons of clarity, a two-dimensional shape space is depicted where the two axis represent independent features of IgG binding, such as charge and size of the binding site. The inhomogeneous IgG shape space distribution under substitution therapy with pooled IgG (bluish area) is represented by the color intensity (arbitrary units). Even if the total amount of administered IgG per treatment is exactly the same, with respect to a specific bacterium, i.e. a specific shape space area (red point), fluctuations occur from treatment to treatment. doi:10.1371/journal.pone.0005685.g001
and the correlation function In the population model, we do not explicitly resolve IgG specificities and different species of bacteria. A detailed description could be realized within the shape space concept [26] . The shape space is an abstract high-dimensional space, where essential features of IgG binding regions with respect to the considered bacteria species are represented as points. In this spirit, points in the shape space become occupied by the pooled IgG that is administered in each treatment. However, the occupation of shape space points does not necessarily occur in a homogenous fashion. As is schematically shown in Figure 1B , even for the same total amount of administered IgG, the amount of IgG that is available to specific shape space areas can be fluctuating from treatment to treatment. Since the immune-response term in Eq. (4) is the product of B m t ð Þ and I m t ð Þ, the fluctuations Eq. (7) in the administered IgG dose per treatment can be viewed as an effective description of shape space inhomogeneities within the population model.
It is straightforward to compute the time-evolution of the serum IgG concentration and the bacteria concentration by numerical integration of Eqs. (1) and (4) . Moreover, the advantage of our model is that it permits to analytically calculate closed expressions for undetermined quantities such as the clearance rate.
Computer Simulations
We perform simulations of the model Eqs. (1) and (4) using a self-written algorithm that is based on the fourth-order accurate Runge-Kutta method [27] . In all simulations the time step of integration is set to the typical infusion duration per treatment, T i , which is estimated to be two hours. The model parameters are summarized in Table 1 and we checked that our numerical results are robust against small variations in the parameter values.
Analytical Calculations
Substitution Therapies in the Absence of Infections. In the absence of infections, the model reduces to Eq. (1) with B m t ð Þ~0 and the source term Eq. (5) for substitution therapy with frequency Eq. (2). It can be easily verified by differentiation that the model is solved by the serum IgG concentration
where the step function,
ensures that only treatments n with nT m ƒt contribute. After N m elapsed treatments, the next treatment takes place at t~0 and the time-evolution of I m t ð Þ during the interval 0ƒtvT m is given by
The number of treatments scales as N m~m N 1 , such that the total elapsed time, N m T m~N1 T 1 , is equal for all m. In the equilibrated system the number of elapsed treatments N m §N 1 &1= r d T 1 ð Þ, implying that Eq. (13) reduces to
where we used the limiting value of the infinite geometric series. The ensemble average of Eq. (14) yields
which is identical to I m t ð Þ in the absence of fluctuations. Furthermore, the ensemble average of I m t ð Þ 2 yields
where we used Eq. (9) and the limiting value of the infinite geometric series. The expression Eq. (16) gives rise to the relative variance
Substitution Therapies in the Presence of Infections
In the presence of fluctuations, we solve Eq. (4) with
where we account for fluctuations around the time-averaged serum IgG concentration SI m t ð ÞT Tm according to Eq. Alternatively, we derive and solve the Fokker-Planck equation that corresponds to Eq. (21) in order to obtain the probability distribution P b m , t ð Þ for the time-dependent bacteria population size.
In general, the probability that the bacteria population has size b m at time tzDt is given by (19), it can be shown that the transition probability reduces to the expression [28] :
Inserting Eq. (23) into Eq. (22) and taking the limit Dt?0 yields the Fokker-Planck equation:
This equation describes the time-evolution of the probability distribution P b m , t ð Þ with initial bacteria concentration
at the time point of infection t i~rp t i :
The coefficients in Eq. (24) are defined by
and
and are derived on the basis of Eq. (21):
We readily obtain 
while the only term contributing to Eq. (27), 
evaluates to
Here, we defined the dimensionless factor c m~wm r
which contains the non-negative quantity w m :s r I m ð Þr p T m 2. For an equilibrated system, the probability distribution is obtained from Eq. (24) under the condition
or, equivalently, as the solution of 
where the distribution has its maximum. The solution of Eq. (36) is given by
where the normalization constant,
contains the Gamma function, C x ½ : Ð ? 0 t x{1 e {t dt, which is valid for xw{1.
We are now in the position to calculate the average size of the bacteria population,
and obtain the result:
Similarly, averaging the square of the bacteria population yields:
such that the relative variance of the distribution is given by
In terms of Eqs. (41)- (43), the probability distribution Eq. (38) can be written in the form
which can be further reduced to the expression Eq. (75).
Since the condition Eq. (34) entails that the time-dependence of P b m , t ð Þis lost, we estimate the clearance time t c after which the infection is cleared in the presence of fluctuations. Victorious fluctuations can compensate for a reduced time-averaged IgG concentration: SĨ I m T Tm ƒSI m T Tm . The condition Eq. (30), which is valid in the absence of fluctuations, translates in formal analogy to Eq. (7) into
To estimate the number of treatments required for the victorious fluctuation to occur, we average the sum of fluctuations for N c treatments,
under the constraint that it yields at least the valuẽ
Thus, on average the victorious fluctuation S v N c ð Þ is given by
in terms of the step function Eq. (12) . The brackets denote the average
with the Gaussian distribution
in terms of the variance Eq. (17) . Using the integral representation of the step function in the complex plane, we have to solve
Taking the average yields
Inserting this expression into Eq. (51) and integrating over y, we obtain the result:
where we introduced C: 
Linearizing the tangens hyperbolicus for r d T 1 = 2m ð Þ~0:28=m%1 yields the expression Eq. (87).
Results
Substitution Therapies in the Absence of Infections
We consider IgG substitution therapies that differ in the treatment frequency in order to compare serum IgG peak levels L p and IgG dosages that are required to maintain the serum IgG trough level L t . Since it has been reported that XLA patients require a trough level of L t~8 g=l to prevent recurrent bacterial infections [13, 15, 16] , we use this value in all calculations. Similarly, we keep the degradation rate r d~0 :02d {1 fixed in all calculations. This value is based on the in vivo half-lifetime for IgG blood products of about 35 days, as consistently reported by the American Society of Health-System Pharmacists [29] and the Canadian Blood Services [30] .
In the absence of infections and fluctuations in the administered IgG dose, the model reduces to Eq. (1) with B m t ð Þ~0 and the source term Eq. (5) with g~0 for substitution therapies of frequency f m . The computed time-evolution of the serum IgG concentration I m t ð Þ is presented in Figure 2A , where we compare four substitution therapies that differ by the time intervals
, and T 8~3 :5 d between subsequent treatments. For substitution therapy with frequency f 1 the simulation predicts that a dose of I 1~6 g=l per treatment is required to maintain the serum IgG trough level L t . This value is in agreement with the empirical protocol of IV infusion therapy, which prescribes 0.4 g IgG per kg body weight every four weeks [14, 15] . For an adult person with a body weight of 75 kg and a blood volume of 5 liters, this implies 30 g IgG per treatment and equals the administered serum IgG concentration of 6 g/l. For substitution therapies with higher frequencies, the simulations predict IgG doses per treatment of I 2~2 :58 g=l for f 2 , I 4~1 :2 g=l for f 4 , and I 8~0 :58 g=l for f 8 . In the case of substitution therapy with treatment frequency f 4 this corresponds to 0.08 g IgG per kg body weight every week and compares reasonably well with extended studies reporting weekly doses in the range 0.051 to 0.147 g IgG per kg body weight [15] . Note that even for comparable body masses, due to the variability in IgG pharmacokinetics, the required IgG dosage always depends on the individual patient. Nevertheless, our simulations have a firm quantitative basis and reproduce values that are in agreement with the range of values obtained from extended experimental studies. This remains true if a constant background of bacteria is taken into account and will be discussed below.
The numerical results of our simulations are confirmed by the analytical solution of the model as derived in the Methods Section [cf Eq. (14)]. It can be rigorously calculated that the serum IgG concentration between two subsequent treatments, 0ƒtvT m , is given by:
In order to compare different substitution therapies, we measure the trough level of the serum IgG concentration at t~T m :
imposing the condition that each treatment maintains the same trough level L t . For the IgG dose per treatment I m , this implies the central relation Figure 2B and observe that the amount of substituted IgG is reduced in therapies with higher frequency f m , both per treatment and also time-integrated. For example, under substitution therapy with frequency f 8 the timeintegrated dose is reduced by 23% as compared to f 1 . Per treatment the IgG dose is even reduced by more than 90% for substitution therapy with frequency f 8 as compared to f 1 . A lower IgG dose per treatment has direct consequences for the IgG peak level
This exponentially decreasing function of m is plotted in Figure 2C . The comparison of substitution therapy f 1 versus f 8 reveals a significant difference in the increase relative to the physiological trough level L t of 75% versus 7%, respectively. In absolute numbers this corresponds to L p 1 ð Þ~14 g=l and L p 8 ð Þ~8:56 g=l and is in agreement with the range of values found in experiment [13, 15] . During the time interval 0ƒtvT m the serum IgG concentration drops from L p m ð Þ to L t , where the corresponding time-averaged serum IgG concentration is defined by
As can be seen in Figure 2C , the relative deviation of SI m t ð ÞT Tm from the trough level L t is only 3.6% for substitution therapy f 8 , which is an order of magnitude smaller than for substitution therapy f 1 with 34%.
Next, we consider the case where fluctuations in the administered IgG dose per treatment are present. As can be observed in Figure 2D for all substitution therapies with the same fluctuation strength g~0:2, the serum IgG trough level L t is still maintained on average. However, variations of I m t ð Þ around L t are larger for substitution therapies with lower frequency f m . This observation can be quantified by the analytical solution of the model as presented in the Methods Section [cf Eq. (17)]. We find that the serum IgG concentration between two subsequent Neglect of fluctuations in the administered IgG dose. In the absence of fluctuations (g~0), we compare the immune response under different substitution therapies. Typical simulation results are plotted in Figure 3 for substitution therapy with frequency f 1 (black line) and f 8 (blue line). Choosing a high value for the clearance rate, r c~4 :0 dg=l ð Þ {1 , the proliferation of bacteria is strongly suppressed under both substitution therapies resulting into the fast extinction of the bacteria population and a virtually unaffected dynamics of the serum IgG concentration ( Figures 3A and 3B) . The situation is different for low clearance rates, where a chronic infection develops that is accompanied by a decrease in the serum IgG concentration. This is shown in Figures 3C and 3D for the clearance rate r c~1 :0 dg=l ð Þ {1 and is qualitatively similar under both substitution therapies. Due to the immune response the growth of the bacteria population is limited to a size lower than the carrying capacity C B . Note that the concentration B m t ð Þ is modulated by the repeated IgG infusions and has an average value that is slightly larger for substitution therapy f 8 as compared to f 1 . The serum IgG trough level for substitution therapy f 1 is slightly more reduced than for substitution therapy f 8 . This is a general feature which can be explained in the limit of a constant bacteria population B m t ð Þ~B with dB m t ð Þ=dt~0. The trough level in the presence of a constant bacteria population follows directly from Eqs. (56) and (57):
Substitution Therapies in the Presence of Infections
For small concentrations B%1= r c T m ð Þ, we obtain to lowest order in the size of the bacteria population:
where we defined
This is a strictly monotonically increasing function of x. Thus, as can be expected, a small constant background of bacteria results only into a modest decrease of the serum IgG trough level. However, as follows from the functional dependence of F r d T 1 =m ð Þ on m, the decrease of the trough level is less pronounced for substitution therapies with higher frequency f m . This result is preserved in the limit of a strong chronic infection, B&1= r c T m ð Þ, where Eq. (64) can be approximated by
In this limit, the immune response against infections consumes significantly more IgG than is lost by its natural degradation. Therefore, the serum IgG trough level becomes exponentially suppressed indicating that the immune response fails to clear the infection. Interestingly, qualitative differences for the two substitution therapies f 1 and f 8 are observed at intermediate values of the clearance rate r c . In Figures 3E and 3F we plot the result for r c~2 :5 dg=l ð Þ {1 and find that a chronic infection develops for substitution therapy f 8 accompanied by a decrease in the corresponding serum IgG trough level. In contrast, for substitution therapy f 1 the initially increasing bacteria population is eventually cleared by the immune response. Shortly after the IgG infusion treatment at day 112 the infection is cleared, even though until this time the bacteria population had grown to a size that is comparable to the final population size of the chronic infection under substitution therapy f 8 .
We investigate the transition from a cleared infection to a chronic infection as a function of the clearance rate r c . This is done by computing the time-averaged value
in the time interval TƒtƒTzDt. The parameters of the time interval are chosen such that the system has time to equilibrate, i.e. we start at time point T~400 days and consider a time interval of Dt~100 days. For different substitution therapies the results are shown in Figure 4 as a function of r c . We find that the critical clearance rate above which chronic infections do not develop depends on the frequency f m of the applied substitution therapy. which decides about the fate of the bacteria population due to the immune response, is given by the ratio of the bacteria proliferation rate to the clearance rate,
and does not depend on the carrying capacity C B .
In the limit of a sufficiently strong immune response with SI m t ð ÞT Tm §K, bacteria are cleared faster than they can proliferate resulting into the complete extinction of the population. In this case the decay of the bacteria population is given by
where we introduced the non-negative parameter
This parameter depends on the applied substitution therapy and determines how fast the bacteria population becomes extinct. The transition from a system with a cleared infection to a system with a chronic infection is determined from s m~0 , or
In Figure 5A we plot K as a function of r c for three different values of the proliferation rate r p . The crossing points of K with SI m t ð ÞT Tm for the four substitution therapies with frequencies f 1 , 62), (69), and (73) we obtain the analytical expression:
The dependence of the critical clearance rate on the bacteria proliferation rate r p is observed in Figure 5A , implying that the success of clearing an infection under substitution therapy with frequency f m strongly depends on the virulency of the bacteria. Note, however, that the critical clearance rate does not depend on the carrying capacity C B .
In Figure 5B we plot the ratio r Figures 6C and 6D but for a different random realization in the administered IgG dose per treatment. In this case it takes about 44 days before the infection is cleared by substitution therapy with frequency f 8 . In general, different random realizations give rise to large variations in the infection duration that can exceed months and years. Therefore, even though the infection may be ultimately cleared, it may still have to be treated as a chronic infection in the sense that additional medication is necessary to clear the infection on a reasonable time scale. This issue will be further addressed below.
The simulations suggest that the critical clearance rate in the presence of fluctuations,r r However, once an infection has been cleared, the bacteria population has died out and is defeated for ever. As is observed in Figure 6 , infections are in fact cleared by victorious fluctuation that happen to occur in the course of time. For example, analyzing substitution therapy with frequency f 1 in Figure 6A , the current peak level at the time point of infection is relatively low and is only increasing above average values in the subsequent treatment at day 140, which then leads to the immediate clearance of the infection. For substitution therapy with frequency f 8 in Figure 6C , such a victorious fluctuation happens to occur around the time point of infection resulting into the immediate clearance of the infection, whereas in Figure 6E it takes until day 125 before a victorious fluctuation is established that ultimately defeats the infection.
Analytical results are obtained by translating the stochastic differential equation (4) into the corresponding Fokker-Planck equation [28] . The latter describes the time-evolution of the probability distribution P B m , t ð Þ for the time-dependent survival of a bacteria population under the immune response. The derivation of the stationary probability distribution P eq B m ð Þ for the equilibrated system is presented in the Methods Section [cf Eq. (44)]. Here, we readily give the final expression in a compact form:
where the normalization constant N~s
Furthermore, we use the scaled variable
while the parameter of the distribution corresponds to the relative variance 
Interestingly, two distinct regimes of P eq z ð Þ are identified that are visualized in Figure 7 . For s r w1 the probability distribution Eq. (75) diverges at z~0, such that the extinction of the bacteria population is most likely to occur in this regime. In contrast, for s r v1 we find that P eq z ð Þ?0 for z?0, meaning that in this regime the extinction of the bacteria population is impossible and a chronic infection is established. The abrupt transition between these two regimes is induced by the fluctuations and occurs at s r~1 , where P eq z ð Þ equals the exponential distribution with a finite value at z~0.
The average size of the bacteria population has been calculated in the Methods Section [cf Eq. (41)] and yields in terms of the model parameters:
where the non-negative quantity 
Here, we defined the strictly monotonic function
such thatr r Figure 8B as solid lines. It is important to notice that, in comparison to the case of absent fluctuations, the difference between substitution therapies in the presence of fluctuations is significantly larger. For g~0 we found that the clearance of infection under substitution therapy with frequency f 8 implies that the critical clearance rate is about 30% larger as compared to substitution therapy with frequency f 1 ( Figure 5B ). However, for fluctuation strength g~0:1, g~0:2, and g~0:3 the critical clearance rate under substitution therapy with frequency f 8 is increased by, respectively, 100%, 200%, and 300% relative to the substitution therapy with frequency f 1 .
Next, as is shown in the Methods Section [cf Eq. (42)], the calculation of the average square of the bacteria population concentration yields
such that the relative variance becomes The derivation of the equilibrium probability distribution Eq. (75) entails that all time-dependent information is lost. As has been stated above, an infection might be cleared at some day but the duration of infection may exceed months and years. We estimate the clearance time in the presence of fluctuations that compensate for a reduced time-averaged IgG concentration: SĨ I m T Tm ƒSI m T Tm . The condition Eq. (73), which was derived in the absence of fluctuations, translates in formal analogy to Eq. (7) into
From the viewpoint of the bacteria population, the non-negative factorC
can be interpreted as a measure for inhomogeneities in the IgG shape space distribution. In order to clear the infection, the deficitC C has to be compensated by victorious fluctuations in the course of time. 
which is independent of the treatment frequency. In Figure 9 
Discussion
Applying a stochastic immune response model, we perform a comparative study of IgG substitution therapies. The combined analysis of computer simulations and analytical calculations permits to make quantitative predictions that are of therapeutic relevance. We base our model on data that are obtained from large-scale studies of IgG substitution therapies [15] . However, to our knowledge, clinical studies where serum IgG levels of a sufficiently large group of patients are monitored for reasonably long times under IgG substitution therapy with varying treatment frequencies do not yet exist. This may be related to the fact that XLA, with an estimated number of 1500 new patients per year worldwide, is a relatively rare immune deficiency. Therefore, mathematical modeling represents the ideal tool for simulating and optimizing IgG substitution therapies under uniquely defined conditions. As a general result of this approach, the behavior of selected quantities is predicted and motivates purposeful experiments.
For IgG substitution therapies with different treatment frequencies we compare serum peak levels and IgG dosages that are required to maintain the same serum trough level. In general, we find that the amount of substituted IgG is reduced for substitution therapies with higher treatment frequencies, both per treatment and also time-integrated ( Figure 2B ). Thus, against the background of the current worldwide IgG shortage and the continuously increasing high costs in the order of 100 US $ per gram IgG [20, 21] , substitution therapies with high treatment frequencies are preferable. In particular, for substitution therapy with two treatments per week relative to substitution therapy with one treatment per four weeks, we find that the IgG dose per treatment is reduced by more than 90% and the time-integrated dose is reduced by more than 20%. This has direct consequences for the serum IgG peak level and the time-averaged serum IgG concentration. Both quantities are exponentially decreasing with the frequency of the substitution therapy ( Figure 2C ). Comparing again substitution therapies with two treatments per week and with one treatment per four weeks, we obtain a significant difference in the increase of the serum IgG peak level relative to the physiological trough level of 7% versus 75%, respectively. Similarly, we find an order of magnitude difference in the deviation of the time-averaged serum IgG concentration from the trough level, which is only 3.6% for substitution therapy with two treatments per week as compared to 34% for substitution therapy with one treatment per four weeks. In general, it can be deduced from Figure 2B and 2C that the characteristic quantities quickly level off for treatment frequencies above once per two weeks.
All these findings support IgG substitution therapies with high treatment frequencies for which the IgG consumption is reduced and where therapeutic serum IgG levels are kept close to physiological levels. This is highly desirable since the precise mechanisms behind immunomodulatory effects of administered IgG are not yet understood, however, it is generally accepted that administered IgG does interfere with the immune system at many different levels [14, 31, 32] . For example, administered IgG has inhibitory effects on antigen presentation [33] , on T cell activation [32, 34, 35] , on cellular cross-talk via the cytokine network [36, 37] , and on phagocytosis via the IgG fragment crystallizable (Fc) region [32, 38, 39] . In general, impaired immune regulation by Fc receptors leads to unresponsiveness or hyperreactivity to non-self as well as self antigens [40] . Moreover, it is reported that administered IgG promotes apoptosis in lymphocytes and monocytes [32, 41] . Taken together, there is sufficient reason for keeping serum IgG levels close to the physiological level.
It should be kept in mind, however, that the primary goal of IgG substitution therapy in XLA patients is the prevention of opportunistic infections. At this point we exploit the advantage of mathematical modeling where different substitution therapies in the presence of bacterial infections can be analyzed under identical conditions as a function of the clearance rate. In general, the value of the clearance rate, which depends on microscopic details of the binding between IgG and antigenic epitopes [42] , is not known. We vary this parameter and find that the infection is cleared under any IgG substitution therapy for sufficiently high clearance rates. However, a critical value of the clearance rate exists below which a chronic infection develops that is accompanied with a decrease in the IgG trough level. As can be seen in Figure 3C and Figure 3D , the bacteria population survives the immune response and grows by a factor 10 6 , while the IgG trough level is only lowered by a factor 0.75. We conclude that small changes in the trough level can be associated with large changes in the bacteria population. Therefore, monitoring the serum IgG trough level in XLA patients on a regular basis provides information for the early detection of infections by systematic deviations.
Our analytical calculations reveal that the critical clearance rate strongly depends on the virulency of the bacteria, since it is proportional to the bacteria proliferation rate. Most importantly, however, the critical clearance rate depends on the applied substitution therapy, as we consistently show by numerical ( Figure 4 ) and analytical ( Figure 5) calculations. In general, a higher critical clearance rate is required for substitution therapies with higher treatment frequencies. This supports IgG substitution therapies with low treatment frequencies in order to optimize the prevention of chronic infections. For example, the substitution therapy with two treatments per week requires the critical clearance rate to be about 30% larger as compared to substitution therapy with one treatment per four weeks ( Figure 5B) . The difference between substitution therapies becomes even more significant in the presence of fluctuations in the administered IgG dose. Comparing the same substitution therapies as before, the predicted increase in the critical clearance rate is of the order of several hundreds of percent with the exact value depending on the fluctuation strength (Figure 8) . Therefore, ignoring the potential impact of immunomodulatory effects and the important issue of IgG shortage, treatment frequencies well below once per week are preferred.
The differences in the critical clearance rate for different substitution therapies are minimized by keeping the fluctuations in the administered IgG dose per treatment small. From the viewpoint of the considered bacteria species, these fluctuations can also be interpreted to effectively model dynamic inhomogeneities of the IgG shape space distribution during the immune response ( Figure 1B) . Even if the time-averaged serum IgG concentration in the relevant shape space area is smaller than is required for the clearance of the infection, it may nevertheless be cleared in the course of time due to victorious fluctuations. Thus, in principle, due to the presence of fluctuations infections are cleared that would otherwise become chronic. However, our model predicts that only small inhomogeneities of the order of several percent are balanced by victorious fluctuations on a reasonable time scale. For larger inhomogeneities the time required for clearing the infection can easily exceed months (Figure 9 ), making additional medication necessary to clear the infection on a reasonable time scale. A side effect of fluctuations is that systematic deviations in the monitored serum IgG trough level get blurred ( Figure 6 ).
In conclusion, the stochastic immune response model emphasizes the importance of elaborate IgG pooling in order to achieve a highly homogeneous IgG shape space distribution for the reliable clearance of infections on a reasonable time scale. For XLA patients the choice of the treatment frequency is a trade-off between competing interests: On the one hand, therapeutic IgG levels should be kept close to physiological levels in order to diminish immunomodulatory effects and to make good economic sense. This is realized by substitution therapies with high treatment frequencies. On the other hand, the regime of clearance rates that are effective at clearing infections is to be maximized. This is achieved by substitution therapies with low treatment frequencies. Taken together, our model suggests that the compromise solution with regard to the treatment frequency of IgG substitution therapy for XLA patients ranges from once per week to once per two weeks.
We finally note that the stochastic immune response model is a first step that can be improved in various ways. For example, the time-evolution of the serum IgG concentration could be more realistically represented in the shape space of IgG specificities to model the simultaneous infection by different bacteria species explicitly. Furthermore, the impact of immunomodulatory effects due to high serum IgG peak levels could be included into the model and analyzed by a comparative study of substitution therapies. Leaving these and related issues for future research, the present study already represents a conclusive example for the potential of mathematical modeling in optimizing empirical IgG treatment protocols. On the basis of our analysis, we suggest clinical studies where the same group of XLA patients is monitored during sufficiently long times for infections and serum IgG levels under different IgG substitution therapies within the specified range of optimal treatment frequencies.
